dockets: DEA-2023-0028

Regulatory dockets from Regulations.gov — containers for related documents and comments in a rulemaking proceeding.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id agency_id title docket_type last_modified object_id rin dkabstract category subtype keywords program short_title effective_date organization attrs_raw attr_source
DEA-2023-0028 DEA Expansion of Induction of Buprenorphine via Telemedicine Encounter (DEA948) Rulemaking 2025-06-02T20:11:54Z 0b0000648572859f 1117-AB78 The Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) are expanding the circumstances under which practitioners registered by the DEA are authorized to prescribe schedule III-V controlled substances approved for the treatment of opioid use disorder via a telemedicine encounter, including an audio-only encounter. Under these regulations, practitioners may prescribe up to an initial six-month supply through audio-only means. Practitioners must review the patient’s prescription drug monitoring program for the state in which the patient is located prior to prescribing. Pharmacists are required to verify the identity of the patient prior to filling a prescription.               {"displayProperties": [], "keywords": null, "modifyDate": "2025-06-02T20:11:54Z", "dkAbstract": "The Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) are expanding the circumstances under which practitioners registered by the DEA are authorized to prescribe schedule III-V controlled substances approved for the treatment of opioid use disorder via a telemedicine encounter, including an audio-only encounter. Under these regulations, practitioners may prescribe up to an initial six-month supply through audio-only means. Practitioners must review the patient\u2019s prescription drug monitoring program for the state in which the patient is located prior to prescribing. Pharmacists are required to verify the identity of the patient prior to filling a prescription.", "agencyId": "DEA", "program": null, "shortTitle": null, "subType2": null, "title": "Expansion of Induction of Buprenorphine via Telemedicine Encounter (DEA948)", "generic": null, "field1": null, "docketType": "Rulemaking", "petitionNbr": null, "rin": "1117-AB78", "organization": null, "legacyId": null, "subType": null, "category": null, "field2": null, "effectiveDate": null, "objectId": "0b0000648572859f"} single_get

Links from other tables